MarketCap
Facebook
X
TelegramQuarterly report 2024-Q3
added 11-07-2024
Lumos Pharma EPS Ratio 2011-2026 | LUMO
EPS is a measure used to assess the financial stability and profitability of a company. EPS (Earnings Per Share) represents the company's net income divided by the number of its outstanding shares. This measure allows investors and analysts to evaluate the return on investment in the company's stock and compare it to other companies in the industry.
The term earnings per share (EPS) represents the portion of a company's earnings, net of taxes and preferred stock dividends, that is allocated to each share of common stock. The figure can be calculated simply by dividing net income earned in a given reporting period (usually quarterly or annually) by the total number of shares outstanding during the same term. Because the number of shares outstanding can fluctuate, a weighted average is typically used.
Calculated as:
EPS = (Net Income - Dividends on Preffered Stock) / Average Outstanding shares[1]
EPS can be calculated as a simple ratio of net income to shares, or in various variations, such as diluted EPS, which takes into account the potential issuance of new shares or convertible securities.
A high EPS ratio usually indicates that the company has good profitability and efficiency in utilizing its assets. However, other factors such as sales growth, debt burden, and the company's competitive position should also be considered.
EPS ratio is an important indicator for investors when making decisions to buy or sell a company's stock. It is also used by analysts to assess the financial condition of the company and its potential for growth and development.
Annual EPS Ratio Lumos Pharma
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -4.18 | -3.71 | -3.65 | -0.93 | -1.15 | -1.44 | -2.3 | -2.94 | -1.41 | 3.45 | -1.23 | -1.12 | -2.98 |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 3.45 | -4.18 | -1.81 |
Quarterly EPS Ratio Lumos Pharma
| 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -0.9 | -0.93 | -1.29 | - | -1.04 | -1.09 | -0.89 | - | -0.86 | -0.94 | -0.92 | - | -0.9 | -0.99 | -1.04 | - | 0.21 | -0.65 | -0.14 | -0.22 | -2.56 | -0.27 | -0.27 | -0.28 | -0.2 | -0.47 | -0.49 | -0.37 | -0.69 | -0.57 | -0.72 | -0.46 | -0.54 | -1.12 | -0.82 | -0.75 | -0.55 | -0.49 | 0.4 | 4.29 | -0.2 | -0.33 | -0.33 | -0.31 | -0.32 | -0.28 | -0.33 | -0.3 | -0.28 | -0.31 | -0.23 | -0.44 | -1.09 | -1.2 | -1.07 |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 4.29 | -2.56 | -0.52 |
References
- Khan, T. R., Islam, M. R., Choudhury, T. T., & Adnan, A. M. (2014). How earning per share (EPS) affects on share price and firm value.
EPS Ratio of other stocks in the Biotechnology industry
| Issuer | EPS Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
-15.4 | - | 2.43 % | $ 254 M |  Germany |
 |
Aligos Therapeutics
ALGS
|
-2.45 | $ 6.4 | - | $ 63.3 M |  USA |
 |
Amphastar Pharmaceuticals
AMPH
|
2.1 | $ 21.41 | - | $ 1 B | USA |
 |
I-Mab
IMAB
|
-7.66 | - | - | $ 866 M |  China |
 |
Aeglea BioTherapeutics
AGLE
|
-24.9 | - | - | $ 1.01 B | USA |
 |
Midatech Pharma plc
MTP
|
-31 | - | -18.52 % | $ 27.3 M |  Britain |
 |
Aptorum Group Limited
APM
|
-0.19 | $ 0.9 | -2.33 % | $ 6.62 M | China |
 |
Biophytis SA
BPTS
|
-0.26 | - | -13.47 % | $ 169 M |  France |
 |
Genfit SA
GNFT
|
1.51 | - | 2.54 % | $ 160 B | France |
 |
ACADIA Pharmaceuticals
ACAD
|
1.37 | $ 21.96 | - | $ 3.64 B | USA |
 |
Cardiff Oncology
CRDF
|
-0.69 | $ 1.72 | - | $ 115 M | USA |
 |
Advaxis
ADXS
|
-7.99 | - | -9.65 % | $ 45.9 M | USA |
 |
AIkido Pharma
AIKI
|
-1.57 | - | 1.93 % | $ 17.4 M | USA |
 |
Esperion Therapeutics
ESPR
|
-0.11 | $ 1.91 | - | $ 397 M | USA |
 |
Akouos
AKUS
|
-2.52 | - | 0.23 % | $ 488 M | USA |
 |
Galectin Therapeutics
GALT
|
-0.48 | $ 2.33 | - | $ 149 M | USA |
 |
Allakos
ALLK
|
-2.14 | - | - | $ 28.6 M | USA |
 |
AlloVir
ALVR
|
-2.85 | - | 4.14 % | $ 49.1 M | USA |
 |
Ampio Pharmaceuticals
AMPE
|
-10.7 | - | -11.43 % | $ 502 K | USA |
 |
Applied Molecular Transport
AMTI
|
-3.25 | - | - | $ 10.1 M | USA |
 |
Aeterna Zentaris
AEZS
|
-0.07 | - | 5.93 % | $ 314 M |  Canada |
 |
Brainstorm Cell Therapeutics
BCLI
|
-1.11 | - | -2.5 % | $ 5.88 M | USA |
 |
Applied Therapeutics
APLT
|
-1.42 | - | - | $ 8.42 M | USA |
 |
Aptinyx
APTX
|
-0.96 | - | -39.0 % | $ 4.57 M | USA |
 |
AgeX Therapeutics
AGE
|
-1.91 | - | -10.17 % | $ 12.2 K | USA |
 |
Aravive
ARAV
|
-2.1 | - | -13.39 % | $ 1.45 M | USA |
 |
Aridis Pharmaceuticals
ARDS
|
-1.62 | - | 17.91 % | $ 11.1 M | USA |
 |
BioNTech SE
BNTX
|
42.2 | $ 105.46 | - | $ 27.2 B | Germany |
 |
Heron Therapeutics
HRTX
|
-0.12 | $ 1.19 | - | $ 198 M | USA |
 |
Avenue Therapeutics
ATXI
|
-0.93 | - | -52.27 % | $ 4.45 M | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
-0.36 | - | - | $ 26.5 M | USA |
 |
ImmuCell Corporation
ICCC
|
-0.12 | $ 8.36 | - | $ 75.5 M | USA |
 |
Aquestive Therapeutics
AQST
|
-0.78 | $ 4.08 | - | $ 436 M | USA |
 |
Arcutis Biotherapeutics
ARQT
|
-0.13 | $ 23.26 | - | $ 2.96 B | USA |
 |
InflaRx N.V.
IFRX
|
-1.26 | $ 1.48 | - | $ 152 M | Germany |
 |
Ayala Pharmaceuticals
AYLA
|
-2.46 | - | - | $ 7.46 M |  Israel |
 |
Autolus Therapeutics plc
AUTL
|
-1.08 | $ 1.44 | - | $ 383 M | Britain |
 |
Aptose Biosciences
APTO
|
-10.4 | - | -45.71 % | $ 1.2 M | Canada |
 |
Innate Pharma S.A.
IPHA
|
-0.66 | $ 1.41 | - | $ 235 M | France |
 |
AstraZeneca PLC
AZN
|
0.08 | - | - | $ 96.9 B | Britain |
 |
Jaguar Health
JAGX
|
-23 | $ 0.39 | -0.18 % | $ 910 K | USA |
 |
AVROBIO
AVRO
|
0.27 | - | 1083.1 % | $ 745 M | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
-5.97 | $ 2.91 | - | $ 4.79 M | Israel |
 |
KalVista Pharmaceuticals
KALV
|
-2.03 | $ 19.63 | - | $ 1.06 B | Britain |
 |
BioDelivery Sciences International
BDSI
|
0.85 | - | -4.8 % | $ 255 M | USA |
 |
Kamada Ltd.
KMDA
|
-0.05 | $ 8.28 | - | $ 260 M | Israel |
 |
BeiGene, Ltd.
BGNE
|
0.2 | - | 0.49 % | $ 251 B |  Cayman-islands |